Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: A case report

Anu Dham, Alexander M. Truskinovsky, Arkadiusz Z. Dudek

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma. We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor. After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins. We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.

Original languageEnglish (US)
Pages (from-to)94-97
Number of pages4
JournalJournal of Thoracic Oncology
Volume3
Issue number1
DOIs
StatePublished - Jan 2008

Bibliographical note

Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.

Keywords

  • Carcinoids
  • Growth factor receptor
  • Neoadjuvant therapy
  • Octreotide
  • Platelet-derived growth factor receptor
  • Somatostatin receptor
  • Sunitinib
  • Vascular endothelial

Fingerprint Dive into the research topics of 'Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: A case report'. Together they form a unique fingerprint.

Cite this